VACCINATED patients with cancer are more likely than those without cancer to contract a breakthrough COVID-19 infection, which puts them at a much higher risk for hospitalization and death, according to new study published in JAMA Oncology. The risks were highest among patients who had certain cancers and those who had received cancer treatment within the past year. “These results emphasize the need for patients with cancer to maintain mitigation practice, especially with the emergence of different virus variants and the waning immunity of vaccines,” the study authors wrote. Researchers at Case Western Reserve University analyzed electronic health record data for more than 636,000 vaccinated patients, including more than 45,000 vaccinated patients with cancer. They looked for the time trends, risks and outcomes of breakthrough COVID-19 infections for vaccinated cancer patients in the U.S. between December 2020 and November 2021. Overall, the cumulative risk of breakthrough infections in vaccinated cancer patients was 13.6%, with the highest risk for pancreatic (24.7%), liver (22.8%), lung (20.4%) and colorectal (17.5%) cancers and the lowest risk for thyroid (10.3%), endometrial (11.9%) and breast (11.9%) cancers, versus 4.9% in vaccinated patients without cancer. Patients who had medical encounters for their cancer within the past year had a higher risk for a breakthrough infection, particularly those with breast cancer, blood cancers, colorectal cancer, bladder cancer and pancreatic cancer. (SD-Agencies) | 